Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's average EBITDA Per Share Growth Rate was 33.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 62.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Oncosem Onkolojik Sistemlernayi ve Ticaret AS was 62.40% per year. The lowest was -18.90% per year. And the median was 62.10% per year.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS 3-Year EBITDA Growth Rate Related Terms
IST:ONCSM vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EBITDA Growth Rate falls into.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 62.10% mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a 3-Year EBITDA Growth Rate of 62.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. This is near median its historical median of 62.10. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #54 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 7.8%.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EBITDA Growth Rate too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current 3-Year EBITDA Growth Rate of 62.10% is near median its 10-year median of 62.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 62.10% is 666.7% above this industry median. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #54 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #54 out of 691 companies for 3-Year EBITDA Growth Rate. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.10. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 62.10% is 666.7% above this benchmark. While the company's 10-year median is 62.10 vs. the industry median of 8.10, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current 3-Year EBITDA Growth Rate of 62.10% is 666.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current 3-Year EBITDA Growth Rate is 62.10%, which is near median its own 10-year median of 62.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺256.54, compared to a current price of ₺262.00 — trading 2.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 62.10%, which is near median its 10-year median of 62.10 and 666.7% above the Medical Devices & Instruments industry median of 8.10. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current 3-Year EBITDA Growth Rate is 62.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺262.00 is trading 2.1% above its estimated GF Value™ of ₺256.54.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:ONCSM:
3-Year EBITDA Growth Rate: 62.10% (near median its 10-year median of 62.10)
GF Value™: ₺256.54 vs. price of ₺262.00 (2.1% above fair value)
Industry Position: 666.7% above the Medical Devices & Instruments median (#54 of 691)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
